A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

NCT04509622 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: Venetoclax
DRUG: Cytarabine

Sponsor

AbbVie